What can we help you find?

October 1, 2013 7:30 am ET

Company to Close Summit Campus; Move Global HQ to Kenilworth

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced plans to move its global headquarters from Whitehouse
Station, N.J., to its existing facilities in Kenilworth, N.J. The
company had previously announced that it would close its Whitehouse
Station building and relocate its global headquarters to Summit, N.J.
However, after re-evaluating its real estate needs in the state, Merck
determined that it could achieve greater cost savings and operational
synergies by closing both its Summit campus and its main Whitehouse
Station facility. The transition is expected to begin next year and be
completed by 2015.

These updated plans are part of the company’s global
initiative announced today, to sharpen its commercial and R&D focus
and reduce costs, including the size of its workforce and global real
estate footprint.

Merck’s Animal Health and Consumer Care divisions currently located in
Summit will be relocated to another facility in New Jersey. In addition,
certain manufacturing, laboratory and other functions currently located
in Summit will be relocated to other facilities in New Jersey or
Pennsylvania.

Merck has been headquartered in Whitehouse Station since 1992. Prior to
1992, the company was headquartered in Rahway, N.J.

About Merck

Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com
and connect with us on Twitter,
Facebook
and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Merck’s ability to accurately
predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other protections
for innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2012 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

Merck
Media:
Lainie Keller, 908-423-4187
Kelley Dougherty, 908-423-4291
Investor:
Carol Ferguson, 908-423-4465
Joe Romanelli, 908-423-5185